New paper out!
We systematically compared how ATN biomarker changes track cognitive decline in AD:
Tau-PET, plasma ptau217 & cortical thickness changes track cognition, amyloid-PET does not.
Ptau217 = cost-effective proxy for monitoring cognitive changes in AD
doi.org/10.1002/alz....
INTRODUCTION
With anti-amyloid beta (Aβ) therapies approved for Alzheimer's disease (AD), surrogate biomarkers are needed to monitor clinical treatment efficacy. Therefore, we systematically compare.....
